These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19322588)

  • 1. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.
    Woerly V; Maynard L; Sanquer A; Eun HM
    Parasitol Res; 2009 Aug; 105(2):463-9. PubMed ID: 19322588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.
    Dos Santos Nogueira F; Avino VC; Galvis-Ovallos F; Pereira-Chioccola VL; Moreira MAB; Romariz APPL; Molla LM; Menz I
    Parasit Vectors; 2019 Feb; 12(1):79. PubMed ID: 30736866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.
    Manna L; Vitale F; Reale S; Picillo E; Neglia G; Vescio F; Gravino AE
    Vet J; 2009 Dec; 182(3):441-5. PubMed ID: 18818112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
    Mateo M; Maynard L; Vischer C; Bianciardi P; Miró G
    Parasitol Res; 2009 Jul; 105(1):155-62. PubMed ID: 19238439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis.
    Dias ÁFLR; Ayres EDCBS; de Oliveira Martins DT; Maruyama FH; de Oliveira RG; de Carvalho MR; Almeida ADBPF; Teixeira ALS; Mendonça AJ; Sousa VRF
    Exp Parasitol; 2020 Oct; 217():107947. PubMed ID: 32628971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.
    Manna L; Corso R; Galiero G; Cerrone A; Muzj P; Gravino AE
    Parasit Vectors; 2015 May; 8():289. PubMed ID: 26017164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.
    Hernández L; Gálvez R; Montoya A; Checa R; Bello A; Bosschaerts T; Jansen H; Rupérez C; Fortin A; Miró G
    Parasitol Res; 2014 Jan; 113(1):157-64. PubMed ID: 24192865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis.
    Miró G; Oliva G; Cruz I; Cañavate C; Mortarino M; Vischer C; Bianciardi P
    Vet Dermatol; 2009 Oct; 20(5-6):397-404. PubMed ID: 20178476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis.
    Daza González MA; Fragío Arnold C; Fermín Rodríguez M; Checa R; Montoya A; Portero Fuentes M; Rupérez Noguer C; Martínez Subiela S; Cerón JJ; Miró G
    Vet J; 2019 Mar; 245():22-28. PubMed ID: 30819422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study.
    Rougier S; Vouldoukis I; Fournel S; Pérès S; Woehrlé F
    Vet Parasitol; 2008 May; 153(3-4):244-54. PubMed ID: 18337012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
    Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of oral miltefosine for visceral leishmaniasis.
    Sundar S; Rosenkaimer F; Makharia MK; Goyal AK; Mandal AK; Voss A; Hilgard P; Murray HW
    Lancet; 1998 Dec; 352(9143):1821-3. PubMed ID: 9851383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and clinical management of canine leishmaniosis by general veterinary practitioners: a questionnaire-based survey in Portugal.
    Monteiro M; Prata S; Cardoso L; Pereira da Fonseca I; Leal RO
    Parasit Vectors; 2021 Jun; 14(1):306. PubMed ID: 34099039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.
    Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Navarro-Moll MC; Morillas-Márquez F; Martín-Sánchez J
    Vet Res Commun; 2018 Jun; 42(2):121-130. PubMed ID: 29453596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    Herwaldt BL
    N Engl J Med; 1999 Dec; 341(24):1840-2. PubMed ID: 10588972
    [No Abstract]   [Full Text] [Related]  

  • 20. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
    Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
    Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.